Urszula Wojtyra

Publication de la version définitive des Lignes directrices du CEPMB

Top Ten Rx IP Update Reads Of 2024

FCA Sets Aside PMPRB's Order That Galderma's Patent Claiming 0.3% Adapalene "Pertained To" 0.1% Adapalene DIFFERIN